Genmab A/S/€GMAB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.
Ticker
€GMAB
Sector
Primary listing
XGAT
Employees
2,639
Headquarters
Copenhagen, Denmark
Website
Genmab A/S Metrics
BasicAdvanced
€15B
13.01
€18.35
0.80
-
Price and volume
Market cap
€15B
Beta
0.8
52-week high
€244.40
52-week low
€154.81
Average daily volume
2.3K
Financial strength
Current ratio
6.216
Quick ratio
6.196
Long term debt to equity
2.49
Total debt to equity
2.791
Interest coverage (TTM)
49.22%
Profitability
EBITDA (TTM)
1,126.929
Gross margin (TTM)
94.54%
Net profit margin (TTM)
37.59%
Operating margin (TTM)
34.95%
Effective tax rate (TTM)
11.77%
Revenue per employee (TTM)
€1,171,560
Management effectiveness
Return on assets (TTM)
13.26%
Return on equity (TTM)
28.12%
Valuation
Price to earnings (TTM)
13.005
Price to revenue (TTM)
4.865
Price to book
20.64
Price to tangible book (TTM)
34.25
Price to free cash flow (TTM)
16.825
Free cash flow yield (TTM)
5.94%
Free cash flow per share (TTM)
14.188
Growth
Revenue change (TTM)
32.97%
Earnings per share change (TTM)
77.72%
3-year revenue growth (CAGR)
31.40%
10-year revenue growth (CAGR)
40.59%
3-year earnings per share growth (CAGR)
31.80%
10-year earnings per share growth (CAGR)
33.13%
Bulls say / Bears say
DARZALEX net trade sales reached USD 3.539 billion in Q2 2025, reflecting strong market uptake and underpinning Genmab’s royalty revenue stream (Genmab press release).
In the first half of 2025, Genmab’s revenue rose 19% year-on-year to USD 1.640 billion, driven by higher DARZALEX and Kesimpta royalties and growing EPKINLY net product sales, demonstrating diversified and growing income sources (Genmab Interim Report H1 2025).
On August 12, 2025, Genmab announced positive Phase II results for Arzerra in previously untreated CLL patients, with overall response rates of 77% and 73% and no unexpected safety findings, expanding its development pipeline into new oncology indications (Reuters).
Morphosys AG filed a patent infringement lawsuit against Genmab and Janssen on April 4, 2025 over daratumumab, exposing Genmab to potential litigation costs and uncertainty around future royalty streams (Reuters).
In Q1 2025, royalty revenue comprised approximately 82% of Genmab’s total revenue (USD 589 million of USD 715 million), indicating heavy reliance on DARZALEX and Kesimpta royalties and concentration risk if these assets face competition or patent challenges (Genmab Q1 report).
Genmab initiated a share buy-back program on March 25, 2025, earmarking up to DKK 4.0 billion to repurchase 2.2 million shares, a capital allocation that may divert funds from R&D investment in its pipeline (Genmab press release).
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab A/S stock?
Genmab A/S (GMAB) has a market cap of €15B as of September 16, 2025.
What is the P/E ratio for Genmab A/S stock?
The price to earnings (P/E) ratio for Genmab A/S (GMAB) stock is 13.01 as of September 16, 2025.
Does Genmab A/S stock pay dividends?
No, Genmab A/S (GMAB) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Genmab A/S dividend payment date?
Genmab A/S (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab A/S?
Genmab A/S (GMAB) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.